Latest Period
Q4 2025
Security Snapshot
REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) Institutional Ownership
CUSIP: 76152G100
13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025
Institutions Reporting
44
Shares (Excl. Options)
11,148,640
Price
$0.28
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- RVPH on Nasdaq
- Shares outstanding
- 12,805,677
- Price per share
- $0.18
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 11,148,640
- Total reported value
- $3,114,479
- % of total 13F portfolios
- 0%
- Share change
- +1,662,587
- Value change
- +$129,897
- Number of holders
- 44
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share is tracked under CUSIP 76152G100.
- 44 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 40 to 44 between Q3 2025 and Q4 2025.
- Reported value moved from $3,493,458 to $3,114,479.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Form 13F
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP 76152G100?
CUSIP 76152G100 identifies RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 76152G100:
Significant Owners of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 9.9% | $3,120,000 | 8,000,000 | HIGHBRIDGE CAPITAL MANAGEMENT, LLC | 30 Jun 2025 | |||
| Bhat Laxminarayan | 3.8% | -28% | $1,877,246 | +$34,930 | 3,680,874 | +1.9% | Bhat Laxminarayan | 22 Sep 2025 |
| 683 Capital Management, LLC | 3% | -47% | $1,257,300 | -$699,300 | 3,492,500 | -36% | 683 CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
| TANG CAPITAL MANAGEMENT LLC | 4.8% | -38% | $1,325,990 | -$199,028 | 3,399,975 | -13% | TANG CAPITAL MANAGEMENT, LLC | 30 Jun 2025 |
| Schonfeld Strategic Advisors LLC | 2.8% | $1,157,125 | 1,314,915 | Schonfeld Strategic Advisors LLC | 31 Dec 2024 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 6.2% | +113% | $174,669 | -$542,018 | 793,952 | -76% | Integrated Core Strategies (US) LLC | 23 Mar 2026 |
| CVI Investments, Inc. | 5.2% | +6% | $146,667 | -$639,086 | 666,667 | -81% | CVI Investments, Inc. | 18 Mar 2026 |
| SAXENA PARAG | 2.8% | -48% | $79,922 | -$1,299,040 | 363,280 | -94% | Parag Saxena | 20 Mar 2026 |
As of 31 Dec 2025, 44 institutional investors reported holding 11,148,640 shares of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH). This represents 87% of the company’s total 12,805,677 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 25% | 3,197,581 | +66% | 0% | $892,125 |
| MILLENNIUM MANAGEMENT LLC | 18% | 2,263,470 | +32% | 0% | $631,508 |
| GEODE CAPITAL MANAGEMENT, LLC | 8.2% | 1,048,954 | +88% | 0% | $292,683 |
| JANE STREET GROUP, LLC | 7% | 894,749 | +292% | 0% | $249,636 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 5.3% | 682,053 | +30% | 0% | $190,293 |
| CITADEL ADVISORS LLC | 4.3% | 554,630 | 0% | $154,742 | |
| STATE STREET CORP | 3% | 383,200 | +202% | 0% | $106,913 |
| BlackRock, Inc. | 2.9% | 371,661 | +546% | 0% | $103,693 |
| UBS Group AG | 2.8% | 359,455 | 0% | $100,288 | |
| MORGAN STANLEY | 2.6% | 337,315 | +8087% | 0% | $94,110 |
| NORTHERN TRUST CORP | 1.6% | 209,373 | +193% | 0% | $58,415 |
| XTX Topco Ltd | 1.3% | 164,291 | +64% | 0% | $45,837 |
| Lido Advisors, LLC | 0.74% | 94,739 | -4.9% | 0% | $31,133 |
| GROUP ONE TRADING LLC | 0.49% | 62,365 | 0% | $17,400 | |
| Focus Partners Wealth | 0.41% | 53,000 | 0% | 0% | $14,787 |
| Corient Private Wealth LLC | 0.3% | 38,000 | 0% | $10,602 | |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.28% | 36,261 | +79% | 0% | $10,120 |
| CUTLER INVESTMENT COUNSEL LLC | 0.26% | 33,500 | 0% | $9,347 | |
| BECKER CAPITAL MANAGEMENT INC | 0.25% | 32,580 | 0% | $9,090 | |
| Creative Planning | 0.25% | 32,107 | 0% | 0% | $8,958 |
| HRT FINANCIAL LP | 0.24% | 31,112 | 0% | $8,000 | |
| TWO SIGMA SECURITIES, LLC | 0.24% | 30,727 | 0% | $8,573 | |
| AQR CAPITAL MANAGEMENT LLC | 0.22% | 28,001 | 0% | 0% | $7,812 |
| Cetera Investment Advisers | 0.19% | 23,800 | -60% | 0% | $6,641 |
| Kestra Advisory Services, LLC | 0.16% | 20,000 | 0% | $5,580 |
Institutional Holders of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 11,148,640 | $3,114,479 | +$129,897 | $0.28 | 44 |
| 2025 Q3 | 9,477,953 | $3,493,458 | -$2,523,110 | $0.37 | 40 |
| 2025 Q2 | 14,276,867 | $5,439,564 | +$2,030,904 | $0.38 | 44 |
| 2025 Q1 | 7,316,794 | $6,939,218 | -$2,147,972 | $0.95 | 47 |
| 2024 Q4 | 7,732,309 | $14,008,817 | -$4,024,379 | $1.81 | 42 |
| 2024 Q3 | 9,947,227 | $14,936,260 | +$4,666,858 | $1.44 | 33 |
| 2024 Q2 | 6,849,687 | $8,748,871 | +$1,342,404 | $1.28 | 30 |
| 2024 Q1 | 5,573,837 | $21,010,997 | -$1,861,302 | $3.78 | 28 |
| 2023 Q4 | 5,266,256 | $27,119,158 | +$12,592,563 | $5.15 | 35 |
| 2023 Q3 | 2,663,385 | $13,004,016 | -$556,556 | $4.88 | 24 |
| 2023 Q2 | 2,636,201 | $15,447,187 | +$8,416,328 | $5.86 | 22 |
| 2023 Q1 | 1,375,662 | $5,761,612 | +$298,180 | $4.19 | 22 |
| 2022 Q4 | 1,303,532 | $5,539,575 | +$1,730,868 | $4.25 | 23 |
| 2022 Q3 | 865,615 | $1,376,000 | -$905,812 | $1.59 | 15 |
| 2022 Q2 | 1,865,547 | $2,053,000 | -$115,802 | $1.10 | 9 |
| 2022 Q1 | 1,902,181 | $4,678,000 | -$2,054,792 | $2.46 | 14 |
| 2021 Q4 | 2,612,910 | $7,543,000 | -$15,645 | $2.89 | 11 |
| 2021 Q3 | 2,603,081 | $10,549,000 | -$229,537 | $4.06 | 11 |
| 2021 Q2 | 2,652,392 | $12,779,000 | +$9,606,649 | $4.86 | 11 |
| 2021 Q1 | 586,328 | $3,365,000 | +$1,292,854 | $5.74 | 7 |
| 2020 Q4 | 360,070 | $3,149,000 | +$3,149,000 | $8.77 | 3 |